Although high high-density lipoprotein (HDL)-cholesterol levels are associated with
decreased cardiovascular risk in epidemiological studies, recent genetic and …

High-density lipoprotein (HDL) has been identified as a potential target in the treatment of
atherosclerotic vascular disease. The failure of torcetrapib, an inhibitor of cholesteryl ester …

The adaptation of adenoviruses as gene delivery tools has resulted in the development of
high-capacity adenoviral vectors (HC-AdVs), also known, helper-dependent or “gutless” …

Population studies have shown that plasma HDL levels correlate inversely with
cardiovascular disease risk. In recent years there has been intense interest in developing …

Last-generation adenovirus vectors, also called helper-dependent or gutless adenovirus,
are very attractive for gene therapy because the associated in vivo immune response is …

There is unequivocal evidence of an inverse association between plasma high-density
lipoprotein (HDL) cholesterol concentrations and the risk of cardiovascular disease, a …

Over the last decade, pioneering liver-directed gene therapy trials for haemophilia B have
achieved sustained clinical improvement after a single systemic injection of adeno …

In this chapter, we review how HDL is generated, remodeled, and catabolized in plasma. We
describe key features of the proteins that participate in these processes, emphasizing how …

Liver X receptors (LXRs) are regulators of cholesterol metabolism that also modulate
immune responses. Inactivation of LXR α and β in mice leads to autoimmunity; however …

Chronic kidney disease (CKD) is associated with development of atherosclerosis and
premature death from cardiovascular disease. The predisposition of patients with CKD to …